These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34293738)

  • 21. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
    Roger SD; Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Cronin M; Meier Y; Larroque S; Macdougall IC;
    Nephrol Dial Transplant; 2017 Sep; 32(9):1530-1539. PubMed ID: 28339831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R; Kusek JW; Pappas MK
    Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
    Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Oral Iron Therapy for Iron Deficiency Anemia Among US Veterans.
    Patel N; Silvey SG; Arora P; Feldman GM
    JAMA Netw Open; 2024 May; 7(5):e2414305. PubMed ID: 38819821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
    Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.
    Gotloib L; Silverberg D; Fudin R; Shostak A
    J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
    Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
    Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
    Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.